Asbestos Research Today is a free monthly online journal that collates and summarizes the latest research about Asbestos, including details on mesothelioma, lung disease, dangers, effects, risks.

CT, RECIST, and malignant pleural mesothelioma.

Nowak AK

Department of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009 Australia. anowak@cyllene.uwa.edu.au

The unique growth pattern of malignant pleural mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting.

Published 13 June 2005 in Lung Cancer, 49: S37-40.
Full-text of this article is available online (may require subscription).

© 2004-2008 Asbestos Research Today. All Rights Reserved.